Westlake BioPartners Fund I Files Schedule 13G for Electra Therapeutics
A Schedule 13G filing for Electra Therapeutics was filed by Westlake BioPartners Fund I, L.P.
Related stories
Regeneron shares rise 11.3% to nearly two-year high after quarterly results exceed expectations
Regeneron shares rose 11.3% to 91, reaching a nearly two-year high after quarterly results exceeded expectations.
M impact | EQUITY | Oct 30, 2026, 02:51 PM UTC
Reddit Shares Tumble More Than 25% After Search Traffic Warning
Reddit shares fell more than 25% Friday morning after a warning about search traffic and user volume in the months ahead. Third-quarter revenue rose more than 50%, but Reddit misse
M impact | EQUITY | Oct 30, 2026, 02:44 PM UTC
ExxonMobil CEO Says Company Intends to Grow Natural Gas Portfolio
M impact | EQUITY | Oct 30, 2026, 02:40 PM UTC
S&P/TSX Composite Falls 1.6% as Base Metals Shares Drop
The S&P/TSX fell 1.6% mid-morning Friday as base metals shares declined.
M impact | EQUITY | Oct 30, 2026, 02:34 PM UTC
Colgate-Palmolive Raises Full-Year Earnings Growth Outlook
Colgate-Palmolive raised its full-year earnings growth outlook after a third-quarter beat.
M impact | EQUITY | Oct 30, 2026, 02:34 PM UTC
US session market picture: S&P 500 -1.54%, Nasdaq 100 -3.03%; EUR/USD -0.3%, WTI +2.25%, WBD leads volume
US session market picture. US index futures: S and P futures is down 1.54 percent, Nasdaq futures is down 3.03 percent, Dow futures is down 0.74 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 02:31 PM UTC